Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corp (NY: GKOS )

50.10 +0.85 (+1.73%)
Official Closing Price Updated: 7:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 370,817
Open 49.56
Bid (Size) 20.04 (1)
Ask (Size) 54.00 (1)
Prev. Close 49.25
Today's Range 49.56 - 50.99
52wk Range 33.33 - 64.49
Shares Outstanding 47,878,462
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It
Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease.  
Via Benzinga
Glaukos Submits New Drug Application to U.S. FDA for iDose TR
From Glaukos Corporation
Via Business Wire

Performance

YTD
+14.18%
+14.18%
1 Month
+1.93%
+1.93%
3 Month
+14.18%
+14.18%
6 Month
-5.58%
-5.58%
1 Year
-17.57%
-17.57%

More News

Read More
NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results
From Glaukos Corporation
Via Business Wire
Earnings Preview For Glaukos
Via Benzinga
Analyst Expectations for Glaukos's Future
Via Benzinga
10 Analysts Have This to Say About Glaukos
Via Benzinga
What 10 Analyst Ratings Have To Say About Glaukos
Via Benzinga
Glaukos Announces Participation in the Citi Healthcare Conference
From Glaukos Corporation
Via Business Wire
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22
From Glaukos Corporation
Via Business Wire
Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability
From Glaukos Corporation
Via Business Wire
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs
From Glaukos Corporation
Via Business Wire
7 Analysts Have This to Say About Glaukos
Via Benzinga
Analyst Ratings for Glaukos
Via Benzinga
Where Glaukos Stands With Analysts
Via Benzinga
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
Via Benzinga
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Via Benzinga
What 4 Analyst Ratings Have To Say About Glaukos
Via Benzinga
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
Glaukos Announces Participation in the Stephens Annual Investment Conference
From Glaukos Corporation
Via Business Wire
Kellogg, Palo Alto Networks, Roku And Other Big Losers From Thursday
Via Benzinga
Glaukos Corporation Announces Third Quarter 2022 Financial Results
From Glaukos Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.